Press release
10 Key Reasons to attend SMi’s 10th Annual Biosimilars Conference
10th Annual Biosimilars Conference
With less than 2 months to go until the 2019 Biosimilars conference, taking place on 25th – 26th September in London, SMi Group have released ten key reasons to be a part of the leading biosimilars event in Europe.
1. Be a part of the discussions on the best practices and techniques to understand the regulatory framework for biosimilars approval
2. Discuss solutions to overcome legal issues with patent protection
3. Explore the latest in regulatory changes and evaluating strategies to ensure compliance, including the revision of the Annex 1, disinfectant validation and methods, endotoxin detection methods and microbiological methods
4. Meet the chair at the two-day conference Michel Mikhail, International Expert in Regulatory Affairs, Global Expert in Biosimilars.
Dr Michel Mikhail has more than 30 years Pharmaceutical Industry experience and a track record of achievement in R&D and International Regulatory Affairs in large multinational research-based pharmaceutical and biotech companies as well as in the generics industry.
5. Discover strategies to source how to make biosimilars a future reliable source
6. Join and network with 90+ attendees at the conference, from the biosimilar industry over the two-day conference and pre-conference workshops
7. Learn about the trends and questions you may have around biosimilars market access policies in the EU
8. Join the two focused pre-conference workshops that will be taking place on Tuesday, 24th September 2019 at the Copthorne Tara Hotel, London on:
Workshop A: USA-FDA Interchangeability Guidelines, led by Michel Mikhail, International Expert in Regulatory Affairs, Global Expert in Biosimilars
Workshop B: Advancing Biosimilars Development and Uptake in MENA & GCC Region, led by Rodeina Challand, General Manager, Challand Biosimilar Consulting
9. Network with the biosimilars experts over 5+ hours of ample networking time over the two-day conference
10. A saving of £499 is available for registrations places by 30th July. Registrations can be made online at http://www.biosimilars-europe.com/openpr4
The updated brochure with the full speaker line-up is now available to download at http://www.biosimilars-europe.com/openpr4
For sponsorship or exhibitor enquiries, please contact Alia Malick on +44 (0)20 7827 6168 or amalick@smi-online.co.uk
For media enquiries, contact Simi Sapal on +44 (0) 20 7827 6000 or email ssapal@smi-online.co.uk
Biosimilars 2019
25th – 26th September 2019
London, UK
http://www.biosimilars-europe.com/openpr4
#SMiBiosimilars
SMi Group
India House
45 Curlew Street
London
SE1 2ND
ssapal@smi-online.co.uk
About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release 10 Key Reasons to attend SMi’s 10th Annual Biosimilars Conference here
News-ID: 1806833 • Views: …
More Releases from SMi Group
Darren Green, GSK, conference chair invitation to attend 3rd Annual AI in Drug D …
SMi Reports: Conference Chairman Darren Green from GSK personally invites you the 3rd Annual AI in Drug Discovery Conference taking place on 14th and 15th March 2022 in London, UK.
The conference will have a focus on case studies from leading pharma and biotech firms, as well as a exploring the latest innovations in machine learning for enhancing discovery pipelines.
Darren Green, Director of Computational Chemistry at GSK will be chairing at…
Registration is open for SMi’s 5th Annual Pharmaceutical Microbiology East Coa …
SMi Group reports: The 5th Annual Pharmaceutical Microbiology East Coast Conference is set to return in April 2022 with a key focus existing methods and novel tools in microbial control to assure continuity in product quality and patient safety.
SMi Group is delighted to announce the 5th Annual Pharmaceutical Microbiology East Coast Conference, taking place on the 27th and 28th April 2022 in Boston, USA.
The 2022 Conference theme is…
SMi’s 10th Annual Pharmaceutical Microbiology UK Conference - A Virtual Confer …
SMi Reports: SMi Group have made the decision to open the microbiology conference and workshops to all microbiologists by transforming it into a virtual-remote online access event only on 17th and 18th January 2022.
SMi’s 10th Annual Pharmaceutical Microbiology UK Conference will no longer take place in London, UK. Instead, the conference is taking place on 17 and 18 January 2022 and will open its doors to a global audience delivering…
Co-chairs Philip Hewitt and Stefan Pryzyborski, invitation to join SMi’s 5th A …
SMi Group reports: Co-Chairs, Philip Hewitt and Stefan Pryzyborski for SMi’s 5th Annual 3D Cell Culture invite industry professionals to join the conference in February 2022.
Philip Hewitt, Global Head of Early Investigative Toxicology, Merck and Stefan Przyborski, Professor in Cell Technology, Durham University invite industry professionals by releasing invite letter to join SMi’s 5th Annual 3D Cell Culture Conference 2022.
This event will convene on February 9th – 10th 2022,…
More Releases for Biosimilar
Infliximab Biosimilar Insight, 2022 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2022" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Interested to know more about the functioning of…
Biosimilar Insulin Market Access
Boston, MA
ReportsWorldwide has announced the addition of a new report title Biosimilar Insulin Market Access to its growing collection of premium market research reports.
Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure.
The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer…
Biosimilar Insulin Market Access
ReportsWorldwide has announced the addition of a new report title Biosimilar Insulin Market Access to its growing collection of premium market research reports.
Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure.
The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer entrants…
Biosimilar Insulin Market Biosimilar Insulin Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
Prologue to Insulin Biosimilars
1.1 Outline Towards Insulin
1.2 Trail of Insulin Evolution and Development
Rationale Design of Insulin Molecule
2.1 Structure of Insulin Polypeptide
2.2 Biosynthesis of Insulin
2.3 Secretion of Insulin
Mechanism of Insulin in Diabetics
3.1 Glucose Metabolism of Insulin
3.2 Impact of Insulin Dysregulation in Diabetes 1
3.3 Impact…
Global Biosimilar Insulin Market To Witness Exponential Growth With 15 Commercia …
“Global Biosimilar Insulin Market Opportunity and Clinical Insight Outlook 2022” report gives comprehensive insight on clinical and non-clinical issues involved with growth of global biosimilar insulin market. This report analyzes various aspects like rationale design of insulin molecule, mechanism of insulin in diabetes, engineering of synthetic insulin, global aspects of biosimilar insulins along with market overview, biosimilar insulin clinical pipeline insight and future trends for the development of…
India Biosimilar Market Analysis
As the number of patent expiries of biologic drugs is increasing, Indian companies are developing biosimilar manufacturing capabilities. Firms are developing their capabilities by either forming partnerships with R&D-intensive firms or outsourcing to upcoming Indian contract research organizations (CROs). Domestic manufacturers have a cost advantage (lower facility and development costs) than peers in developed countries. Moreover, Indian firms seem keen on repeating their successes achieved in developing and commercializing biosimilars.…
